{"id":"W2053180027","doi":"10.1016/j.urology.2008.08.128","title":"POD-6.12: Progression Free Survival in Patients with Metastatic and Recurrent Renal Cancer Treated with Sorafenib: Single Center Experience","year":2008,"lang":"en","type":"article","venue":"Urology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Sorafenib; Renal cell carcinoma; Oncology; Internal medicine; Single Center; Progression-free survival; Overall survival; Kidney cancer; Population; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005180314,0.0001835594,0.0004845263,0.0001921725,0.0004425961,0.0007070976,0.0002162851,0.0003061847,0.0007865922],"category_scores_gemma":[0.001087745,0.0001153267,0.0003901632,0.000386095,0.0002205786,0.0003590509,0.0002992155,0.0003944662,0.0001213845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000584476,"about_ca_system_score_gemma":0.0004476227,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002956379,"about_ca_topic_score_gemma":0.005278747,"domain_scores_codex":[0.9997644,0.00006771934,0.00001665967,0.00004342593,0.00003940935,0.00006836121],"domain_scores_gemma":[0.9995084,0.00008355187,0.000134988,0.00001912451,0.00003969339,0.0002142502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00399381,0.0006899201,0.9593833,0.00003709455,0.0002100381,0.001121636,0.0005188652,0.0006729949,0.002220133,0.00006517912,0.0007687188,0.03031833],"study_design_scores_gemma":[0.0002542732,0.003574926,0.9900765,0.00001179988,0.0001812848,0.003138209,0.0004080655,0.0009256776,0.0006140969,0.00004438524,0.0007505394,0.00002042351],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991398,0.0002917892,0.00005889552,0.00005177579,0.000005645416,0.000004633021,0.00009354057,0.000003423804,0.000350571],"genre_scores_gemma":[0.9995857,0.0001035119,0.00005722362,0.00002140743,0.000009571219,0.000002669298,0.0001183135,0.000002030761,0.00009966432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002956379,"threshold_uncertainty_score":0.005878389,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02554722578655104,"score_gpt":0.2795757208078784,"score_spread":0.2540284950213273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}